Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 95
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04717700 | Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients | ||
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer) | ||
| NCT02471911 | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | ||
| NCT04856189 | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma | ||
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | ||
| NCT02091245 | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | ||
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | ||
| NCT03071276 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | ||
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma | ||
| NCT04349098 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | ||
| NCT02606461 | Selinexor in Advanced Liposarcoma | ||
| NCT01607905 | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | ||
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | ||
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | ||
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | ||
| NCT02336815 | Selinexor Treatment of Refractory Myeloma | ||
| NCT05983276 | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | ||
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease | ||
| NCT02416908 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT06399640 | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | ||
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | ||
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | ||
| NCT04562870 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | ||
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | ||
| NCT02249091 | A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | ||
| NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | ||
| NCT03193437 | Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy | ||
| NCT05530421 | Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma | ||
| NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | ||
| NCT02093403 | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT03555422 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | ||
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | ||
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | ||
| NCT02741388 | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | ||
| NCT02384850 | Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer | ||
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | ||
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | ||
| NCT04607772 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | ||
| NCT02831686 | A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma | ||
| NCT01896505 | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma | ||
| NCT02213133 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas | ||
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | ||
| NCT04519476 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | ||
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | ||
| NCT04843579 | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients | ||
| NCT02227251 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | ||
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | ||
| NCT02402764 | Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) | ||
| NCT02303392 | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | ||
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) |
